Re BioPartnering Europe 2011 Conference

RNS Number : 1440P

ValiRx PLC

29 September 2011

 

29 September 2011

ValiRx Plc

("ValiRx" or the "Company")

VALIRX TO PRESENT DATA RE THERAPEUTIC PROGRAMME PROGRESS

AT BIOPARTNERING EUROPE 2011

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that it will be presenting data on previously announced progress relating to its GeneICE, VAL101 and VAL201 therapeutic programmes* to the BioPartnering Europe 2011 Conference, held in London between 9 and 11 October 2011. The Company also intends to hold a series of one to one partnering meetings during the conference with pharmaceutical companies, other Biotech companies and investors.

BioPartnering Europe is Europe's longest running life science partnering event, connecting and promoting innovation within and serving the needs of the European life science industry, investors and dealmakers for nearly 20 years.

Dr Satu Vainikka, CEO, commented: "I am delighted that ValiRx will be presenting at BioPartnering Europe.   This will be an excellent opportunity to promote the Company's therapeutic programmes within the bio-pharmaceutical community and particularly so after our previously announced, very encouraging progress. I look forward to our further developing new relationships in the industry with a variety of parties".

-     ENDS -

*  ValiRx programmes:

GeneICE is a technology platform for silencing rebellious genes

VAL 101 has been shown to be effective treating several cancer cell lines 

VAL 201 has shown in-vivo efficacy treating hormone-induced tumour growth and other conditions

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.ValiRx.com
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

·       ValiMedix is the sales and distribution division of ValiRx

·       ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments

Background to GeneICE & Eurostars

In June 2009, ValiRx, as the leading partner of an international consortium of three companies, was awarded a two year grant by Eurostar against substantial competition from across Europe, to develop its GeneICE technology ("GeneICE" or "Gene inactivation by chromatin engineering"), in which "rebellious genes", which cause problems such as cancer and potentially some neurological problems, are shut down or "put on ice".

The Eurostars programme is a EU grant scheme and EUrEKa Network initiative, created with the purpose of providing funding for market-oriented research and development activities by Small and Medium-sized Enterprises within the EU.

ValiRx successfully led the funding application with GenoSyst (Finland) and PentaBase (Denmark) under the 2nd call to the Eurostars joint Programme, for design optimisation, lead selection and pre-clinical testing of GeneICE. The application was rated second in the UK and Finland and first in Denmark, coming in 4th overall out of over 500 applicants within the EU wide scheme.

The technology is under license from Imperial College, University of London and it has been shown to be effective against several cancer cell lines, including prostate cancer, ovarian cancer, pancreatic cancer and lung cancer. ValiRx retains all commercial rights for GeneICE from the programme.

The GeneICE development plan has four principal goals:

1.   Identification of specific genomic DNA sequences associated with proven cancer targets.

2.   Design and optimisation of the anti-gene system to silence the aberrant genes

3.   Evaluation of desired and potential off-target effects

4.   Pre-clinical development of an optimised lead therapeutic against a selected target

 

END

 

 

NRAEAKNPALEFEFF